Clinical Trials

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT06072781 2026-03-17

RAMP 301

270 enrolled

Low Grade Serous Ovarian Cancer

NCT07060807 2026-03-16

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

1,000 enrolled

Breast Neoplasms

NCT07214779 2026-03-16

MAESTRA 2

466 enrolled

Ovarian Neoplasms

NCT04729387 2026-03-13

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

358 enrolled

Ovarian Neoplasms

NCT06312176 2026-03-13

MK-2870-010

1,200 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms

NCT04895358 2026-03-11

KEYNOTE-B49

340 enrolled

Phase 3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

NCT02446600 2026-03-05

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

579 enrolled 17 charts

Phase 3 Not yet recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05411237 2026-01-23

Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma

130 enrolled

Sarcoma

AIDS-related Kaposi sarcoma, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT07218809 2026-01-16

TREVI-OC-01

1,100 enrolled

Phase 3 Not yet recruiting

Carcinoma, Ovarian Epithelial

NCT07286266 2025-12-16

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Ovarian Neoplasms

NCT05092360 2025-08-28

ARTISTRY-7

456 enrolled 19 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04209855 2025-08-27

MIRASOL

453 enrolled 18 charts 1 FDA

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT03598270 2024-08-30

ANITA

417 enrolled

Ovarian Neoplasms

NCT05159193 2024-02-02

Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer

372 enrolled

Breast Neoplasms

NCT02584478 2023-11-08

AL3818

294 enrolled

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

566 enrolled 40 charts

Ovarian Neoplasms

NCT00326456 2023-03-27

MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer

820 enrolled

Ovarian Neoplasms

NCT01802749 2023-03-24

MITO16MANGO2b

406 enrolled

Ovarian Neoplasms

NCT00129389 2023-03-07

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

1,925 enrolled 19 charts

Breast Neoplasms

NCT01379989 2022-02-09

INOVATYON

617 enrolled

Ovarian Neoplasms

NCT01170650 2021-09-30

PROCEED

441 enrolled

Neoplasms, Ovarian Neoplasms

NCT04679064 2021-08-27

NItCHE-MITO33

427 enrolled

Ovarian Neoplasms

NCT02903004 2021-08-25

MITO23

242 enrolled

Ovarian Neoplasms

NCT02631876 2020-10-14

FORWARD I

366 enrolled 20 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02421588 2020-04-03

CORAIL

442 enrolled 33 charts

Ovarian Neoplasms

NCT01935492 2020-01-18

Stop&Go

420 enrolled

Breast Neoplasms

NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

581 enrolled 14 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03359694 2017-12-02

Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer

300 enrolled

Breast Neoplasms, Genetic Predisposition to Disease

NCT00097981 2017-04-07

A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

225 enrolled 14 charts

Plasma cell

Multiple Myeloma

NCT03023358 2017-01-18

Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients

174 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01840943 2015-12-23

A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

32 enrolled 13 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Neoplasms, Ovarian Neoplasms

NCT02428751 2015-11-18

R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma

216 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00103506 2015-10-19

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

646 enrolled 10 charts

Plasma cell

Multiple Myeloma

NCT00082095 2014-10-09

To Compare Treatment With Doxorubicin or Capecitabine for Metastatic Breast Cancer in Women 60 Years and Older

62 enrolled

Breast Neoplasms

NCT00113607 2014-06-27

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

672 enrolled 14 charts

Ovarian Neoplasms

NCT00091442 2014-04-21

A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer

751 enrolled 10 charts

Breast Neoplasms

NCT00350948 2013-11-27

ASSIST-5

244 enrolled

Ovarian Neoplasms

NCT00653952 2010-04-27

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

220 enrolled

Ovarian Neoplasms

NCT00191607 2007-01-26

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

162 enrolled